BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23001293)

  • 1. Overexpression of p53 protein in human tumors.
    Inoue K; Kurabayashi A; Shuin T; Ohtsuki Y; Furihata M
    Med Mol Morphol; 2012 Jun; 45(3):115-23. PubMed ID: 23001293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The aberrant p53 protein (review).
    Furihata M; Sonobe H; Ohtsuki Y
    Int J Oncol; 1995 Jun; 6(6):1209-26. PubMed ID: 21556660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Friend or Foe: MicroRNAs in the p53 network.
    Luo Z; Cui R; Tili E; Croce C
    Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
    Hernández Borrero LJ; El-Deiry WS
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The cooperation between p53 and Ras in tumorigenesis].
    Wei YY; Hou J; Tang WR; Luo Y
    Yi Chuan; 2012 Dec; 34(12):1513-21. PubMed ID: 23262097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 as a guardian of the cancer cell.
    Mantovani F; Collavin L; Del Sal G
    Cell Death Differ; 2019 Jan; 26(2):199-212. PubMed ID: 30538286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor p53 and its mutants in cancer metabolism.
    Liu J; Zhang C; Hu W; Feng Z
    Cancer Lett; 2015 Jan; 356(2 Pt A):197-203. PubMed ID: 24374014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Mutant p53 in the Non-Coding RNA World.
    Di Agostino S
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
    Bellutti F; Tigan AS; Nebenfuehr S; Dolezal M; Zojer M; Grausenburger R; Hartenberger S; Kollmann S; Doma E; Prchal-Murphy M; Uras IZ; Höllein A; Neuberg DS; Ebert BL; Ringler A; Mueller AC; Loizou JI; Hinds PW; Vogl C; Heller G; Kubicek S; Zuber J; Malumbres M; Farlik M; Villunger A; Kollmann K; Sexl V
    Cancer Discov; 2018 Jul; 8(7):884-897. PubMed ID: 29899063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promyelocytic leukemia protein is required for gain of function by mutant p53.
    Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
    Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in p53 research and cancer treatment.
    Suzuki K; Matsubara H
    J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 rescue and modulation of p53 redox state.
    Bykov VJ; Lambert JM; Hainaut P; Wiman KG
    Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
    Pfister NT; Prives C
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.